• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Pitriya-T
    / Taro International Ltd


    Active Ingredient

    Status in Israel
    OTC

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft

    Cream

    1 x 15 gr

    not in the basket chart

    Cream

    1 x 30 gr

    not in the basket chart

    Dosage

    Tinea pedis (interdigital), Tinea corporis/cruris: Once per day for 1 week.
    Tinea pedis plantaris (moccasin-type):
    Twice per day for 2 weeks.
    Skin candidiasis: 1-2 times per day for 1 week.
    Tinea versicolor: 1-2 times per day for 2 weeks.


    Indications

    Fungal infections of the skin caused by dermatophytes such as trichophyton (e.g. T. rubrum, T. mentagrophytes, T. verrucosum, T. violaceum) Microsporum canis and Epidemophyton floccosum.
    Yeast infections of the skin principally those caused by the genus Candida (e.g. candida albicans)
    Pityriasis (tinea versicolor) due to pityrosporum orbiculare (also known as malassezia furfur).
    For the treatment of plantar-type tinea pedis (Moccasin type).


    Contra-Indications

    Hypersensitivity to the active substance or to any of the inactive ingredients.


    Special Precautions

    This medicinal product is not recommended for use in children under 12 years old.
    For external use only. Contact with the eyes should be avoided.
    This medicinal product contains cetyl alcohol and stearyl alcohol, which may cause local skin reactions (e.g. contact dermatitis).


    Side Effects

    The application may cause local reactions such as pruritus, desquamation, pain or irritations, pigmentation disorder, burning sensations, erythema or scab. In case of accidental contact with the eyes, eye irritation may occur. In rare cases, the underlying fungal infection may be aggravated.


    Drug interactions

    There are no known drug interactions with the cream.


    Pregnancy and Lactation

    Pregnancy:
    No controlled studies are available in pregnant women. Reproduction studies in animals did not demonstrate any risk for the foetus. This medicinal product should not be used during pregnancy unless absolutely necessary.
    Lactation:
    Terbinafine is excreted in small quantities in breast milk. It is not known if this small amount present in the breast milk may have a deleterious effect on the infant. This medicinal product should not be used while breastfeeding. Young children should not come in contact with the treated skin areas.


    Overdose

    Please refer to the license holder for further details.


    Manufacturer
    Taro Pharmaceuticals Inc., Canada

    סרגל נגישות

    CLOSE